- Home
- A-Z Publications
- Current Drug Targets
- Previous Issues
- Volume 17, Issue 15, 2016
Current Drug Targets - Volume 17, Issue 15, 2016
Volume 17, Issue 15, 2016
-
-
Future Targets in Endothelial Biology: Endothelial Cell to Mesenchymal Transition
Authors: Pei-Yu Chen and Michael SimonsEndothelial to mesenchymal transition (EndMT) is a poorly understood phenomenon that results in normal endothelial cells acquiring a mesenchymal phenotype. EndMT has been observed in a number of pathological conditions, from cancer to fibrosis to cardiovascular disease and the process itself may play an important mechanistic role in the development of these disease states.
-
-
-
Antiangiogenic Resistance and Cancer Metabolism: Opportunities for Synthetic Lethality
Authors: Simon Lord, Juan M. Funes, Adrian L Harris and Miguel Quintela-FandinoAntiangiogenic resistance is a major problem in cancer therapeutics. Preclinical research has identified several compensatory proangiogenic pathways that arise upon vascular endothelial growth factor inhibition, several of which have led to the development of novel drugs. However, the combination of two or more targeted agents in the angiogenesis system is hampered by toxicity, as the system is involved in normal phy Read More
-
-
-
Antiangiogenic Resistance: Novel Angiogenesis Axes Uncovered by Antiangiogenic Therapies Research
Authors: Gabriela Jiménez-Valerio and Oriol CasanovasThe mechanisms of tumor growth and progression involve the activation of different processes such as neovascularization and angiogenesis. These processes involve tumoral cells and stromal cells. Hence, inhibiting angiogenesis affects tumor growth and proliferation in patients with different types of cancer. Nevertheless, tumoral cells and stromal components are responsible for the resistance to antiangiogenic therapies. The Read More
-
-
-
Antiangiogenics and Hypoxic Response: Role of Fatty Acid Synthase Inhibitors
Authors: Maria Jose Bueno, Jesus Sanchez, Ramon Colomer and Miguel Quintela-FandinoOne proposed mechanism through which antiangiogenics exert their effect in epithelial malignancies is by improving the status of the aberrant vascular network and secondarily facilitating the delivery of concurrently administrated cytotoxic agents. During this process, known as vascular normalization, the oxygenation of the tumor is usually improved. Many mechanisms of resistance have been proposed to evade the acti Read More
-
-
-
The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy
Authors: Michalis Mastri, Spencer Rosario, Amanda Tracz, Robin E. Frink, Rolf A. Brekken and John M. L. EbosDrug resistance remains an ongoing challenge for the majority of patients treated with inhibitors of the vascular endothelial growth factor (VEGF) pathway, a key regulator of tumor angiogenesis. Preclinical models have played a significant role in identifying multiple complex mechanisms of antiangiogenic treatment failure. Yet questions remain about the optimal methodology to study resistance that may assist in making clin Read More
-
-
-
Pazopanib in Renal Cell Carcinoma Dialysis Patients: A Mini-Review and a Case Report
Background: Sporadic data are available about pazopanib use in patients with metastatic renal cell carcinoma (mRCC) undergoing dialysis and no systematic review has been previously performed about this issue. Objective: The objective of the present mini-review is to provide an overview of clinical outcomes of pazopanib in this population, in order to support the clinical oncologist for the treatment choice and management. Read More
-
-
-
The Roles of Sox Family Genes in Sarcoma
Authors: Jingyuan Li, Jacson Shen, Kunzheng Wang, Francis Hornicek and Zhenfeng DuanSox (SRY-related HMG-box) family genes are important regulators of cell development, homeostasis, and regeneration. Deregulation of certain members of the Sox gene family has been implicated in a number of human malignancies, including in sarcoma. Accumulating evidence suggests that Sox genes play crucial roles in sarcoma cell pathogenesis, growth, and proliferation. Here, we review the biological relevance of So Read More
-
-
-
Design of Lipophilic Prodrugs to Improve Drug Delivery and Efficacy
Authors: Abhirup Mandal, Mitesh Patel, Ye Sheng and Ashim K. MitraPoor absorption, short half-life and resistance development are some of the major factors responsible for reduced drug efficacy. Lipophilic prodrugs can offer certain advantages to overcome these challenges. Chemical derivatization of hydrophilic agents with lipophilic pro-moieties can significantly elevate drug diffusion across absorptive membranes. Moreover, the desired linkage (ester vs. amide) may be selected to im Read More
-
-
-
Chemical Modifications and Biological Activities of Polysaccharides
Authors: Gangliang Huang, Xin Chen and Hualiang HuangThe chemical modifications of polysaccharides involve the use of chemical methods to modify some special structures or functional groups of polysaccharides on the main chains or side chains. The chemical methods include sulfation, phosphorylation, acetylation, carboxymethylation etc. Therefore, spatial structures, and physical and chemical properties of polysaccharides change, which enhance the biological activities of Read More
-
-
-
Recent Advancements in Diagnosis and Therapy of Liver Cirrhosis
Authors: Roberto Giulio Romanelli and Cristina StasiCirrhosis is a diffuse pathophysiological state of the liver considered to be the final stage of various liver injuries, characterized by chronic necroinflammatory and fibrogenetic processes, with subsequent conversion of normal liver architecture into structurally abnormal nodules, dense fibrotic septa, concomitant parenchymal exaustment and collapse of the liver tissue. Alcoholic liver disease and chronic infections due t Read More
-
-
-
Gastric Carcinoma at the Era of Targeted Therapies
Authors: Johann Dreanic, Marion Dhooge, Elena Sion, Catherine Brezault, Stanislas Chaussade and Romain CoriatGastric and gastro-esophageal cancers (GC/GEJ) appear as the second cancer-related death worldwide. Diagnosis is made at an advanced stage offering a curative attempt in less than 50% of cases. Despite the improvements of the systemic cytotoxic chemotherapy regimens, the prognosis of patients with metastatic GC/GEJ cancer remains poor. Recent insights in biochemical pathways have permitted to identify potential tar Read More
-
Volumes & issues
-
Volume 26 (2025)
-
Volume 25 (2024)
-
Volume 24 (2023)
-
Volume 23 (2022)
-
Volume 22 (2021)
-
Volume 21 (2020)
-
Volume 20 (2019)
-
Volume 19 (2018)
-
Volume 18 (2017)
-
Volume 17 (2016)
-
Volume 16 (2015)
-
Volume 15 (2014)
-
Volume 14 (2013)
-
Volume 13 (2012)
-
Volume 12 (2011)
-
Volume 11 (2010)
-
Volume 10 (2009)
-
Volume 9 (2008)
-
Volume 8 (2007)
-
Volume 7 (2006)
-
Volume 6 (2005)
-
Volume 5 (2004)
-
Volume 4 (2003)
-
Volume 3 (2002)
-
Volume 2 (2001)
-
Volume 1 (2000)
Most Read This Month
Article
content/journals/cdt
Journal
10
5
false
en
